NCT05977322View on ClinicalTrials.gov

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 6, 2023

Primary Completion Date

December 13, 2024

Study Completion Date

December 13, 2024

Conditions
Pancreatic Ductal AdenocarcinomaGastroesophageal AdenocarcinomaGlioblastoma Multiforme
Interventions
DRUG

68Ga-FF58

Kit for radiopharmaceutical preparation of 68Ga- FF58 solution for injection

DRUG

177Lu-FF58

Solution for injection/infusion

Trial Locations (5)

28034

Novartis Investigative Site, Madrid

6423906

Novartis Investigative Site, Tel Aviv

6500HB

Novartis Investigative Site, Nijmegen

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

CH 1211

Novartis Investigative Site, Geneva

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY